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Heart disease comprises a wide class of cardiovascular abnormalities, including ischemic
heart disease, myocardial infarction, atherosclerosis, and coronary artery disease. It is the
leading cause of death all over the world. Several traditional and novel risk factors, such as
infectious and noninfectious agents, have been associated with heart disease. Out of these,
Helicobacter pylori has been recently introduced as an important etiological factor for heart
disease. Numerous seroepidemiological ﬁndings observed H. pylori antibodies in the blood
of  a patient with cardiovascular complications. The bacteria survive in the epithelial cells of
gastric organs and cause digestive complications. Excess inﬂammatory pathogenesis and
prognosis stimulate an immune response that further causes signiﬁcant disturbances in
various factors like cytokines, ﬁbrinogen, triglycerides, high density lipoprotein, C-reactive
protein, heat shock protein, and white blood cell count, and provoke a number of problems
such as atherosclerosis and prothrombic state, and cross-reactivity which eventually leads
to  heart diseases. H. pylori releases toxigenic nutrients, chieﬂy vacuolating cytotoxin gen
A  (Vac A) and cytotoxin associated gene A (Cag A), of which Cag A is more  virulent and
involved in the formation of cholesterol patches in arteries, induction of autoimmune dis-order, and release of immune mediated response. Although numerous mechanisms have
been  correlated with H. pylori and heart disease, the exact role of bacteria is still ambiguous.
©  2016 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license1.  IntroductionIntroduction of heart disease to the medical community has
been a focus of debate, due to the continuously increasing
rate of mortality in developed and developing countries.1–3
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Heart diseases or cardiovascular diseases describe several
heart disorders, including elevated blood pressure, coronary
artery disease, and blockage of the arteries. A number ofh Marathwada University, Dnyanteerth, Vishnupuri, Nanded 431
diseases related to the heart and blood vessels can come
under the umbrella of heart.4 Diverse risk factors such as
hypertension, increased lipid level, obesity, diet with high
dicine. Published by Elsevier. This is an open access article under
nd/4.0/).
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at, physical inactivity, diabetes, and stress conditions are
enerally associated with it. Certain microorganisms such
s Chlamydia pneumoniae, Cytomegalovirus, Epstein-Barr virus,
uman immunodeﬁciency virus, Herpes simplex, and Heli-
obacter pylori contribute in the development of heart diseases
nd are considered as risk factors and infectious.5–8
H. pylori infection has been reported as an important cause
f chronic gastrodigestive ulcers, however the epidemiolog-
cal study based on discovery of bacteria during the past
wo decades has suggested that the higher prevalence of H.
ylori infection might be involved in the pathogenesis of heart
isease.9–13 In recent years, a theory has been proposed that a
acterium is one of the potential mechanisms that can cause
irect and indirect effects on heart disease. Inﬂammatory
nd immunological events provoked by the H. pylori infec-
ion are the main underlying causes of the heart disease.14–16
he effect of infection on cardiovascular physiology can be
irect and indirect. The direct effect includes endothelial
njury, dysfunction through circulating endotoxins, smooth
uscle proliferation, and local inﬂammation, whereas the
ndirect effect includes proinﬂammatory, hypercoagulability,
therogenic action, production of cross reactive antibod-
es, oxidation of low density lipoprotein, molecular mimicry,
xidative modiﬁcation as well as nutrient/vitamin malabsorp-
ion and metabolic disturbances such as excess ammonia
roduction.17–23 Recent studies suggested that a highly vir-
lent strain of H. pylori [cytotoxin associated gene A (Cag A)
train] was more  strongly associated with the risk of heart
iseases which was conﬁrmed by the presence of anti H. pylori
ntibodies through seroprevalence.24,25 The objective of the
resent review is to highlight all possible mechanisms respon-
ible for heart disease in relation with H. pylori infection.
.1.  H.  pylori
he presence of a spiral-shaped bacterial microorganism was
escribed by Professor W.  Jaworski at Cracow in Jagiellonian
niversity, Kraków, Poland. Later, Marshall and Warren27 cul-
ured an organism from a gastritis patient which was not
xactly the same as any previous species; it perhaps belonged
o the Campylobacter genus, so they named it “pyloric campy-
obacter” which was later changed to Campylobacter pylori,
nd after that, it was named H. pylori due to its distinct
orphogenic structural and genetic features. It has a hetero-
eneous morphology and normally it is present in a helicoidal,
piral, or curved shape, while in aged culture it is observed in
occoid form.26–32
H. pylori is a unipolar and microaerophilic bacterium.
t contains ﬁve major outer membrane protein families.
he largest family is putative adhesions whereas the other
our families include porins, iron, transporters, ﬂagellum-
ssociated proteins, and proteins of unknown function. As it
s a Gram-negative bacterium, its outer membrane consists
f phospholipids and lipopolysaccharides and it also contains
holesterol glucosides, which are found in a few other bacte-
ia. The high motility of the bacteria is due to the presence
f two to six lophotrichous ﬂagella. These sheathed ﬂagel-
ar ﬁlaments are composed of two copolymerized ﬂagellins;
agellin A and ﬂagellin B.33–37 They are about 0.5–1 mm in
iameter and 2.5–5.0 mm long. They require about 5% oxygen245
(O2) and 5–10% carbon dioxide (CO2). H. pylori produces oxi-
dase, catalase, and urease enzymes. The ability of the bacteria
to survive in the harsh environment of the stomach is because
of urease synthesis, a powerful enzyme which converts urea,
a chemical made by stomach cells, to carbon dioxide and
ammonia. This in turn creates a protective environment to
the bacteria, by neutralizing acidity in the mucus surrounding
the bacteria.38–42 The variability among strains of H. pylori is
due to the availability of multiple bacterial genome sequences.
It is one of the most genetically diverse species of bacteria,
as it produces a wide range of toxins. Due to high virulent
factors, it has been linked with many  diseases. These viru-
lent factors mainly include vacuolating cytotoxin gene A (Vac
A) production and Cag A. About 50% of H. pylori strains pro-
duce Cag A which has been speciﬁcally linked to heart disease.
These toxigenic nutrients of H. pylori cause inﬂammation to
host cells and strong cellular damage, and rapidly stimulate
host factors such as interleukins (ILs; IL-1, IL-2, IL-6, IL-8, and
IL-12), interferon-gamma, tumor necrosis factor-, T and B
lymphocytes, and phagocytic cells, thereby increasing chances
of heart disease.43–48
1.2.  Association  between  H.  pylori  and  heart  diseases
Several studies have ruled out and it has been suggested that
H. pylori infection is not only linked to gastroduodenal condi-
tions, but also extragastroduodenal conditions such as heart
disease. The bacterial role in several diseases has been stud-
ied on the basis of serological surveillance.49–54 Although these
studies have too many  biases, for the awareness of the people
regarding this asymptomatic infection, a hypothesized theory
has been made using epidemiological and pathological studies
which might be responsible for heart disease.
H. pylori is one of the most widespread infections in the
world. Although H. pylori infection is common, it is difﬁcult
to identify. The delayed diagnosis of infection exaggerates
numerous problems, thus, epidemiological studies are gener-
ally preferred to recognize the incidence of H. pylori infection.
Several studies have been executed for evaluating H. pylori
incidences and prevalence, transmission of infection, and
associated risk factors responsible for the infection. It has
been evident that the prevalence of infection was erratic
from region to region, between the socioeconomic and eth-
nic groups. Three main factors, namely rate of acquisition of
infection (incidences), the rate of loss of infection; and pro-
longed prevalence of the bacterial infection and eradication
are mainly responsible for H. pylori infection in the community.
The prevalence of infection is about 60–70% in adults and
increases with age, while in children it is 20–30%. Its preva-
lence is greater in men  than in women and many  studies
have shown that nonHispanic blacks and Hispanics are more
prone to infection than the White population.55–59 The exact
mode of H. pylori infection transmission is not clear, but sev-
eral transmission mechanisms have been suggested such as
direct transfer from person to person (via fecal-oral or oral-
oral routes), epidemiological factors (food borne, water borne),
and some zoonotic transmission (primates, domestic cats, and
sheep). It is speciﬁcally seen in poorly sanitized people, in
crowded living conditions, and with diminished hygiene.60–67
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2.  Pathological  mechanism
No single factor could account for infection related heart
diseases, as the infection is a multifactorial process. Sev-
eral potential mechanisms and pathways allied with H. pylori
contribute in infection-induced cardiovascular complications.
Fig. 1 brieﬂy focuses on different mechanisms by which H.
pylori contributes to heart diseases.
Inﬂammation is a protective multistep process of the
immune system. Repeated exposure to H. pylori infection leads
to failure of the inﬂammation process and inability to com-
bat progress of infectious agents, which leads to a number of
diseases such as heart disease and cancer. This continuous
over stress causes weakening of the body.68–72 Chronic stim-
ulation of inﬂammatory responses due to bacterial infection
in gut and gastric organs further produces induction of dysli-
pidemia, increases the levels of ﬁbrinogen, stimulates release
of C-reactive protein, escalates blood leukocytes and homo-
cysteine, induces hypercoagulability, stimulates immune
cross-reactivity, increases proinﬂammatory cytokines (ILs,
lymphocytes) and other cytotoxic agents. This dramatic rise
in the production of various proinﬂammatory and inﬂamma-
tory metabolites affects blood vessel motility and provokes
endothelial dysfunctioning, which results in blocking of arter-
ies, thereby increasing the chances of heart attack. It has
been reported that C-reactive protein is a potential indicator
of disease associated with the heart and may play a crucial
role in vessel mortality. Bacterial infection also enhances the
release of IL-8, a small peptide (chemokine) secreted by various
cell types, which serves as a potent inﬂammatory mediator
recruiting and activating neutrophils such as T and B lym-
phocytes. Thus, chronic H. pylori infection results in disturbed
immune response, which ultimately contributes to cardiovas-
cular abnormalities including coronary artery diseases.73–75
Increased inﬂammation and cellular damage caused by
adhesion of H. pylori infection in the body may increase the
release of toxins such as Cag A and Vac A. Recently, it has
been revealed that Cag A positive strain has been linked to
H. pylori-associated heart disease more  virulently than the
Fig. 1 – Helicobacter pylori infection induced immune
response
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Cag-A negative strain. It has been observed that Cag A strains
enhance the activity of cycloxygenase-1 and -2 in vascu-
lar endothelial cells. Also, Cag A-induced inﬂammation may
encourage the immune-mediated release of cytokines such
as IL1–12, monocytes, macrophages (tumor necrosis factor
), and T and B lymphocytes, thereby causing heart disease
or heart shock. Also, an autoimmune reaction could be pos-
tulated which includes cross-reactivity between anti-Cag A
antibodies and vascular wall antigens, suggesting that these
antibodies may contribute to the activation of inﬂammatory
cells within atherosclerotic lesions.76–80
H. pylori infection exaggerates disturbances in the
metabolism of lipid and lipoprotein. Triglyceride levels usu-
ally rise and the level of high density lipoprotein-cholesterol
decreases. This could be due to the involvement of cytokines,
especially tumor necrosis factor-, which inhibits lipoprotein
lipase and enhances free radical generation. This in turn facil-
itates the oxidation of low density lipoprotein, which is a key
event in atherosclerosis. Free radicals also provoke activation
of platelet and leukocyte chemotaxis, and might be respon-
sible for thrombus formation. Increased release of various
factors such as ﬁbrinogen, C-reactive protein, tumor necro-
sis factor, IL-6, and white blood cell count might induce a
prothrombotic state.81–83
Some studies revealed that H. pylori also decreases absorp-
tion of iron through reduction of the ferric to the ferrous form.
Generally, this reaction is enhanced by ascorbic acid, but in the
presence of H. pylori infection, decreases its concentration. It
has been suggested that there is a competition between the
bacteria and host for iron, as it is an essential element for
growth. Thus, starvation of iron results in pernicious anemia,
which further leads to the reduction in the number of circu-
lating red blood cells, bleeding, and malabsorption of vitamin
B12.84,85
H. pylori burden contains a protein on the arterial cell
surface that is similar to the heat shock protein-60 found
in endothelial cells. Therefore, an immune response to H.
pylori may induce immune cross-reaction between human and
bacterial heat shock protein-60, which in turns leads to an
autoimmune reaction and local inﬂammation of the artery.86
There is also speculation regarding the role of H. pylori in
atherosclerotic plaque development, because some studies
have found bacterial deoxyribonucleic acid in arterial plaques
where it forms patches of infection, which results in heart
disease.86
3.  Conclusion
Infection of H. pylori bacteria infection is directly or indirectly
involved in the development of cardiovascular diseases.
Several serological based ﬁndings have revealed the active
role of H. pylori in heart diseases. Activation of inﬂamma-
tory mediators, proinﬂammatory factors, release of toxins,
abnormal lipid metabolism, altered iron metabolism, and
autoimmune reaction are the leading mechanisms of H. pylori,
which contributes in cardiovascular anomalies. The chief
leading role in the cause of heart disease is the improper
functioning of the immune system, both at the cellular and
systemic level. Most of these ﬁndings are based on serological
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ndings. Further studies are needed to recognize the exact
nvolvement of H. pylori in these diseases.
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